Strides Pharma Science Ltd (IN:STAR)
:STAR
Want to see IN:STAR full AI Analyst Report?
Top Page
Strides Pharma Science Ltd
(STAR)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹1,148.00
▲(20.75% Upside)
Action:ReiteratedDate:01/31/26
The score is driven primarily by improving financial performance and healthy cash generation, tempered by historical earnings volatility and some balance sheet constraints. Technicals are a secondary drag due to weak trend signals (negative MACD and price below key moving averages), while valuation is supportive with a reasonable P/E and modest yield.
Positive Factors
Free cash flow generation
Sustained free cash flow provides durable internal funding for working capital, capex and debt reduction. Over the next 2–6 months strong FCF lowers refinancing risk, supports steady operations and gives management flexibility to invest in capacity or absorb temporary margin pressure without needing external finance.
Negative Factors
Historical earnings volatility
Past swings into negative operating results signal earnings cyclicality and execution risk. Such volatility complicates forecasting and may reflect product concentration, regulatory setbacks or pricing shocks, increasing the chance that recent improvements could reverse under adverse market or competitive conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow generation
Sustained free cash flow provides durable internal funding for working capital, capex and debt reduction. Over the next 2–6 months strong FCF lowers refinancing risk, supports steady operations and gives management flexibility to invest in capacity or absorb temporary margin pressure without needing external finance.
Read all positive factors
Strides Pharma Science Ltd (STAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹101.16B
Dividend Yield0.41%
Average Volume (3M)12.54K
Price to Earnings (P/E)10.3
Beta (1Y)0.82
Revenue Growth4.40%
EPS Growth89.29%
CountryIN
Employees3,065
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)21.90
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.40
Price to Sales (P/S)1.37
P/FCF Ratio13.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72.63
Revenue Forecast (FY)₹56.49B
Strides Pharma Science Ltd Business Overview & Revenue Model
Company Description
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The com...
How the Company Makes Money
Strides makes money mainly by selling generic pharmaceutical products and related pharmaceutical supply/services across multiple geographies. Its revenue model is primarily based on (1) finished dosage form (FDF) sales: income from marketing and d...
Strides Pharma Science Ltd Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
65
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.85B | 44.75B | 38.28B | 36.68B | 30.59B | 32.80B |
| Gross Profit | 16.59B | 11.83B | 8.51B | 8.05B | 4.11B | 9.59B |
| EBITDA | 8.78B | 7.10B | 5.15B | 3.66B | -214.95M | 5.17B |
| Net Income | 3.97B | 4.05B | -1.20B | -2.21B | -4.60B | 2.55B |
Balance Sheet | ||||||
| Total Assets | 65.21B | 60.49B | 58.40B | 66.38B | 69.76B | 70.15B |
| Cash, Cash Equivalents and Short-Term Investments | 2.27B | 2.06B | 2.90B | 3.61B | 1.84B | 2.75B |
| Total Debt | 18.44B | 18.80B | 25.17B | 30.30B | 30.25B | 23.48B |
| Total Liabilities | 37.18B | 34.62B | 37.68B | 44.66B | 45.93B | 42.01B |
| Stockholders Equity | 27.56B | 25.52B | 21.26B | 22.12B | 23.59B | 27.77B |
Cash Flow | ||||||
| Free Cash Flow | 2.42B | 4.42B | 5.83B | -505.27M | -4.01B | 1.84B |
| Operating Cash Flow | 3.91B | 6.84B | 7.01B | 444.11M | -2.58B | 4.81B |
| Investing Cash Flow | -1.48B | -896.89M | -1.50B | 3.02B | -1.19B | -5.21B |
| Financing Cash Flow | -2.33B | -6.43B | -6.93B | -2.14B | 4.21B | -157.96M |
Strides Pharma Science Ltd Technical Analysis
Positive
950.75
Price Trends
903.18
Positive
900.07
Positive
886.11
Positive
Market Momentum
30.59
Negative
67.67
Neutral
76.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:STAR, the sentiment is Positive. The current price of 950.75 is below the 20-day moving average (MA) of 953.99, above the 50-day MA of 903.18, and above the 200-day MA of 886.11, indicating a bullish trend. The MACD of 30.59 indicates Negative momentum. The RSI at 67.67 is Neutral, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:STAR.
Strides Pharma Science Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹823.37B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
73 Outperform | ₹389.99B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
72 Outperform | ₹639.49B | 25.97 | ― | 0.80% | 11.73% | 10.02% | |
66 Neutral | ₹606.72B | 59.42 | ― | 0.15% | 27.46% | 320.69% | |
65 Neutral | ₹101.16B | 10.27 | ― | 0.41% | 4.40% | 89.29% | |
53 Neutral | ₹656.07B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:STAR
Strides Pharma Science Ltd
1,052.55
402.93
62.03%
IN:ALKEM
Alkem Laboratories Ltd.
5,411.30
428.99
8.61%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,421.30
216.13
17.93%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,404.95
1,024.14
74.17%
IN:IPCALAB
IPCA Laboratories Limited
1,539.10
148.13
10.65%
IN:LAURUSLABS
Laurus Labs Ltd.
1,090.40
474.00
76.90%
Strides Pharma Science Ltd Corporate Events
Strides Pharma Wins USFDA Closure for Key New York Formulations Plant
Feb 5, 2026
Strides Pharma Science Limited announced that its U.S. subsidiary, Strides Pharma Inc., has received an Establishment Inspection Report from the USFDA confirming closure of a recent inspection at its formulations facility in Chestnut Ridge, New Yo...
Strides’ US Unit Wins USFDA Closure for New York Formulations Plant, Bolstering U.S. Growth Plans
Feb 5, 2026
Strides Pharma Inc., the U.S. subsidiary of Strides Pharma Science Limited, has received a closure report (Establishment Inspection Report) from the USFDA for its formulations facility at Chestnut Ridge, New York, following an inspection conducted...
Strides Pharma to Engage Investors at Manthan Systematix Annual India Conference
Feb 4, 2026
Strides Pharma Science has notified the stock exchanges that it will participate in the Manthan – Systematix Annual India Conference in Mumbai on February 10, 2026, where it will hold in-person group and one-on-one meetings with analysts and...
Strides Pharma Publishes Unaudited Q3 and Nine-Month FY25 Results Extracts
Jan 31, 2026
Strides Pharma Science Ltd has published extracts of its unaudited financial results for the quarter and nine months ended 31 December 2025 in the Financial Express and Lokmat newspapers, in line with regulatory disclosure requirements. The compan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.